Financials
| Annual Report 2024 published | Feb. 27, 2025 |
| Financial Statement 1 January to 31 December 2024 | Feb. 27, 2025 |
| Faron 2024 Half-Year Financial Results | Aug. 27, 2024 |
| Faron´s Annual Report 2023 | Mar. 26, 2024 |
| Financial Statement January 1 to December 31 2023 | Mar. 13, 2024 |
| Faron 2023 Half-Year Financial Results | Aug. 29, 2023 |
| Faron´s Annual Report 2022 Published | Mar. 03, 2023 |
Proxies
| Results of the Annual General Meeting | Apr. 05, 2024 |
| Notice of Annual General Meeting 2024 | Mar. 13, 2024 |
| Results of AGM | Mar. 24, 2023 |
| Notice of Faron Pharmaceuticals Ltd’s AGM | Mar. 03, 2023 |
| Results of AGM | Apr. 22, 2022 |
| Notice of Faron Pharmaceuticals Ltd’s AGM | Mar. 25, 2022 |
| Result of AGM | Apr. 23, 2021 |
Ownership Update
| Holding(s) in Company | Feb. 14, 2025 |
| Holding(s) in Company | Feb. 06, 2025 |
| Grant of options | Aug. 30, 2024 |
| Grant of options | Aug. 07, 2024 |
| Holding(s) in Company - Replacement | Jun. 25, 2024 |
| Announcement of Placing | Apr. 04, 2024 |
| Grant of options | Dec. 04, 2023 |
Announcements
| FDA Grants Orphan Drug Designation | Mar. 03, 2025 |
| Notice of Financial Statement and Annual Report | Feb. 19, 2025 |
| Change of Broker | Feb. 11, 2025 |
| Results of Oversubscribed Placing | Feb. 06, 2025 |
| Proposed Issue and Placing | Feb. 05, 2025 |
| Final Patient Identified for BEXMAB Phase II Study | Jan. 31, 2025 |
| Faron’s Financial Calendar for 2025 | Dec. 13, 2024 |